Vaishali Pharma profitability ratios

·UnclassifiedChart ›
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026
Returns
6.2%6.2%
3.6%3.6%
4.9%4.9%
3.3%3.0%
Margins
3.9%3.8%
3.2%3.2%
5.0%5.0%
4.1%3.8%
−0.0%−0.0%
Additional
21.2%25.2%
6.2%6.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

VAISHALI₹6.87

Vaishali Pharma Limited

· Unclassified
₹ CrorePeersTEMBOTOTALOSWALSEEDSGROBTEABEARDSELLHINDCONCROWNARTNIRMANMcap ₹44.8 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity———6.216.21
Return on Assets———3.573.57
Return on Capital Employed———4.854.85
Return on Invested Capital———3.043.31
Margins
EBITDA Margin———3.783.92
Operating Margin———3.233.23
Pretax Margin———4.954.99
Net Income Margin———3.834.11
FCF Margin———-0.02-0.02
Additional
Effective Tax Rate———25.1621.21
Sustainable Growth Rate———6.216.21
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.